QIAGEN N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.98 USD | +0.70% |
|
+4.63% | -4.01% |
| May. 02 | QIAGEN Announces the Availability of QCI Secondary Analysis | CI |
| Apr. 30 | QIAGEN NV : Berenberg reaffirms its Buy rating | ZD |
Presenter SpeechCasey Woodring (Analysts)Great. Thank you, everybody. Thanks for joining us to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
2024-05-15
- Berenberg MDx Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
42.98
USD
Average target price
50.19
USD
Spread / Average Target
+16.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.01% | 9.47B | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Transcript : Qiagen N.V. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01
